NO20062793L - Angiogeneseinhiberende molekyler og deres anvendelse ved behandling og diagnostikk av cancer - Google Patents
Angiogeneseinhiberende molekyler og deres anvendelse ved behandling og diagnostikk av cancerInfo
- Publication number
- NO20062793L NO20062793L NO20062793A NO20062793A NO20062793L NO 20062793 L NO20062793 L NO 20062793L NO 20062793 A NO20062793 A NO 20062793A NO 20062793 A NO20062793 A NO 20062793A NO 20062793 L NO20062793 L NO 20062793L
- Authority
- NO
- Norway
- Prior art keywords
- molecules
- angiogenesis
- jam
- cancer
- treatment
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Biotechnology (AREA)
- Animal Behavior & Ethology (AREA)
- Hospice & Palliative Care (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Den foreliggende oppfinnelsen er relatert til angiogeneseinhiberende molekyler som er monoklonale antistoff H33 eller fragmenter eller derivater derav, til deres anvendelse i behandlingen av cancer, spesielt behandlingen av solide tumorer og til terapeutiske og diagnostiske sammensetninger som omfatter dem. Oppfinnelsen er spesielt relatert til humaniserte derivater av H33 eller humane, monoklonale antistoffer som har spesifisiteten av H33.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP03026629A EP1533617A1 (en) | 2003-11-19 | 2003-11-19 | Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer |
US10/738,123 US7642341B2 (en) | 2003-12-18 | 2003-12-18 | Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer |
PCT/EP2004/013247 WO2005050213A1 (en) | 2003-11-19 | 2004-11-19 | Angiogenesis inhibiting molecules and their use in the treatment and diagnosis of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20062793L true NO20062793L (no) | 2006-08-18 |
Family
ID=34621557
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062793A NO20062793L (no) | 2003-11-19 | 2006-06-15 | Angiogeneseinhiberende molekyler og deres anvendelse ved behandling og diagnostikk av cancer |
Country Status (19)
Country | Link |
---|---|
US (1) | US7790863B2 (no) |
EP (2) | EP1533617A1 (no) |
JP (1) | JP2007515159A (no) |
KR (1) | KR101135834B1 (no) |
CN (1) | CN1890567B (no) |
AT (1) | ATE493657T1 (no) |
AU (1) | AU2004291989B2 (no) |
BR (1) | BRPI0415541B8 (no) |
CA (1) | CA2546406C (no) |
DE (1) | DE602004030819D1 (no) |
EA (1) | EA009037B1 (no) |
ES (1) | ES2358905T3 (no) |
HK (1) | HK1097908A1 (no) |
IL (1) | IL175686A (no) |
MX (1) | MXPA06005523A (no) |
NO (1) | NO20062793L (no) |
SG (1) | SG148190A1 (no) |
WO (1) | WO2005050213A1 (no) |
ZA (1) | ZA200603069B (no) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ514091A (en) * | 1999-03-11 | 2004-01-30 | Rmf Dictagene S | Vascular adhesion molecules and modulation of their function |
US7642341B2 (en) | 2003-12-18 | 2010-01-05 | Merck Serono S.A. | Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer |
AU2007301599B2 (en) * | 2006-09-28 | 2013-01-10 | Merck Serono S.A. | Junctional Adhesion Molecule-C (JAM-C) binding compounds and methods of their use |
US20110189653A1 (en) * | 2008-03-21 | 2011-08-04 | Wim Van Criekinge | Detection and prognosis of cervical cancer |
US8962274B2 (en) | 2009-02-27 | 2015-02-24 | Novartis Ag | Methods for selecting eukaryotic cells expressing a heterologous protein |
EP2670772B1 (en) | 2011-02-02 | 2016-07-20 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Antagonists of grasp55 for use as a medicament |
WO2012160031A1 (en) * | 2011-05-24 | 2012-11-29 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Method for prognosing solid tumor outcome |
US9803014B2 (en) | 2012-10-24 | 2017-10-31 | Research Development Foundation | JAM-C antibodies and methods for treatment of cancer |
GB201415367D0 (en) * | 2014-08-29 | 2014-10-15 | Iles Raymond K And Docherty Suzanne M E And Abban Thomas And Naase Mahmoud And Iles Jason K | Methods for detecting abnormalities in haemoglobin |
WO2016156400A1 (en) * | 2015-03-31 | 2016-10-06 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New biomarker for outcome in aml |
RU2599545C1 (ru) * | 2015-11-06 | 2016-10-10 | государственное бюджетное образовательное учреждение высшего профессионального образования "Московский государственный медико-стоматологический университет имени А.И. Евдокимова" Министерства здравоохранения Российской Федерации | Способ подавления роста опухоли основе in vitro репрограммирования макрофагов на м1 фенотип с повышенной способностью к продукции оксида азота в эксперименте |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB8823869D0 (en) * | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US6075181A (en) * | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
US5545806A (en) * | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
US5877397A (en) * | 1990-08-29 | 1999-03-02 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US5789650A (en) * | 1990-08-29 | 1998-08-04 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5633425A (en) * | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
US5625126A (en) * | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
US5661016A (en) * | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
US6300129B1 (en) | 1990-08-29 | 2001-10-09 | Genpharm International | Transgenic non-human animals for producing heterologous antibodies |
US5814318A (en) * | 1990-08-29 | 1998-09-29 | Genpharm International Inc. | Transgenic non-human animals for producing heterologous antibodies |
JP2938569B2 (ja) * | 1990-08-29 | 1999-08-23 | ジェンファーム インターナショナル,インコーポレイティド | 異種免疫グロブリンを作る方法及びトランスジェニックマウス |
US5874299A (en) * | 1990-08-29 | 1999-02-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
WO1992022645A1 (en) | 1991-06-14 | 1992-12-23 | Genpharm International, Inc. | Transgenic immunodeficient non-human animals |
WO1993001227A1 (en) | 1991-07-08 | 1993-01-21 | University Of Massachusetts At Amherst | Thermotropic liquid crystal segmented block copolymer |
JPH08509612A (ja) | 1993-04-26 | 1996-10-15 | ジェンファーム インターナショナル インコーポレイテッド | 異種抗体を産生することができるトランスジェニック非ヒト動物 |
CU22615A1 (es) * | 1994-06-30 | 2000-02-10 | Centro Inmunologia Molecular | Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos |
CN101333516A (zh) | 1995-08-29 | 2008-12-31 | 麒麟医药株式会社 | 嵌合体动物及其制备方法 |
ES2169864T3 (es) * | 1996-05-31 | 2002-07-16 | Health Research Inc | Anticuerpos monoclonales anti-endoglina y su uso en terapia anti-angiogenesis. |
NZ514091A (en) * | 1999-03-11 | 2004-01-30 | Rmf Dictagene S | Vascular adhesion molecules and modulation of their function |
IL148079A0 (en) | 1999-08-24 | 2002-09-12 | Medarex Inc | Human ctla-4 antibodies and compositions containing the same |
MXPA03001915A (es) * | 2000-08-03 | 2004-09-10 | Therapeutic Human Polyclonals | Produccion de anticuerpos humanizados en animales transgenicos. |
TWI313299B (en) | 2000-11-30 | 2009-08-11 | Medarex Inc | Transgenic transchromosomal rodents for making human antibodies |
WO2003006673A2 (en) * | 2001-07-11 | 2003-01-23 | Texas Biotechnology Corporation | A nucleic acid encoding a human junctional adhesion protein (jam3) |
US20050159587A1 (en) * | 2001-07-16 | 2005-07-21 | Heuer Josef G. | Extracellular junctional adhesion molecules |
US20030035802A1 (en) * | 2001-08-14 | 2003-02-20 | Dewan Zeng | Localization of A2B AdoR on human normal and diseased tissue: the use of anti-A2B antibody to diagnose and treat human tumors |
EP1471938A4 (en) | 2002-01-09 | 2008-03-05 | Medarex Inc | HUMAN MONOCLONAL ANTIBODIES AGAINST CD30 |
ES2373947T3 (es) * | 2002-12-16 | 2012-02-10 | Genmab A/S | Anticuerpos monoclonales humanos contra interleucina 8 (il-8). |
EP1572748B1 (en) | 2002-12-17 | 2010-06-23 | MERCK PATENT GmbH | Humanized antibody (h14.18) of the mouse 14.18 antibody binding to gd2 and its fusion with il-2 |
US7642341B2 (en) * | 2003-12-18 | 2010-01-05 | Merck Serono S.A. | Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer |
-
2003
- 2003-11-19 EP EP03026629A patent/EP1533617A1/en not_active Withdrawn
-
2004
- 2004-11-19 US US10/579,105 patent/US7790863B2/en not_active Expired - Fee Related
- 2004-11-19 KR KR1020067009463A patent/KR101135834B1/ko active IP Right Grant
- 2004-11-19 BR BRPI0415541A patent/BRPI0415541B8/pt not_active IP Right Cessation
- 2004-11-19 AT AT04798043T patent/ATE493657T1/de not_active IP Right Cessation
- 2004-11-19 MX MXPA06005523A patent/MXPA06005523A/es active IP Right Grant
- 2004-11-19 CN CN2004800340309A patent/CN1890567B/zh not_active Expired - Fee Related
- 2004-11-19 SG SG200808589-6A patent/SG148190A1/en unknown
- 2004-11-19 EA EA200600995A patent/EA009037B1/ru not_active IP Right Cessation
- 2004-11-19 DE DE602004030819T patent/DE602004030819D1/de active Active
- 2004-11-19 WO PCT/EP2004/013247 patent/WO2005050213A1/en active Application Filing
- 2004-11-19 JP JP2006540362A patent/JP2007515159A/ja active Pending
- 2004-11-19 EP EP04798043A patent/EP1685405B1/en active Active
- 2004-11-19 ES ES04798043T patent/ES2358905T3/es active Active
- 2004-11-19 ZA ZA200603069A patent/ZA200603069B/en unknown
- 2004-11-19 AU AU2004291989A patent/AU2004291989B2/en not_active Ceased
- 2004-11-19 CA CA2546406A patent/CA2546406C/en not_active Expired - Fee Related
-
2006
- 2006-05-16 IL IL175686A patent/IL175686A/en active IP Right Grant
- 2006-06-15 NO NO20062793A patent/NO20062793L/no not_active Application Discontinuation
-
2007
- 2007-04-24 HK HK07104284.0A patent/HK1097908A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
US7790863B2 (en) | 2010-09-07 |
AU2004291989A1 (en) | 2005-06-02 |
CA2546406C (en) | 2013-04-09 |
EA009037B1 (ru) | 2007-10-26 |
EP1685405B1 (en) | 2010-12-29 |
JP2007515159A (ja) | 2007-06-14 |
KR20060130562A (ko) | 2006-12-19 |
IL175686A (en) | 2012-02-29 |
BRPI0415541A (pt) | 2006-12-26 |
BRPI0415541B8 (pt) | 2021-05-25 |
ZA200603069B (en) | 2007-09-26 |
CN1890567A (zh) | 2007-01-03 |
SG148190A1 (en) | 2008-12-31 |
BRPI0415541B1 (pt) | 2018-11-27 |
WO2005050213A1 (en) | 2005-06-02 |
ATE493657T1 (de) | 2011-01-15 |
MXPA06005523A (es) | 2006-12-14 |
KR101135834B1 (ko) | 2012-04-16 |
US20070202110A1 (en) | 2007-08-30 |
EA200600995A1 (ru) | 2006-10-27 |
HK1097908A1 (en) | 2007-07-06 |
AU2004291989B2 (en) | 2009-08-06 |
DE602004030819D1 (de) | 2011-02-10 |
CA2546406A1 (en) | 2005-06-02 |
ES2358905T3 (es) | 2011-05-16 |
IL175686A0 (en) | 2006-09-05 |
EP1685405A1 (en) | 2006-08-02 |
CN1890567B (zh) | 2012-12-12 |
EP1533617A1 (en) | 2005-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062793L (no) | Angiogeneseinhiberende molekyler og deres anvendelse ved behandling og diagnostikk av cancer | |
WO2006055638A3 (en) | Fully human monoclonal antibodies to il-13 | |
WO2006020269A3 (en) | Biomarkers of neurodegenerative disease | |
EP2363404A3 (en) | PSMA antibodies | |
WO2004018649A3 (en) | Monoclonal antibodies and complementarity-determining regions binding to ebola glycoprotein | |
WO2008067464A3 (en) | NEW Aβ CONFORMER SELECTIVE ANTI-Aβ GLOBULOMER MONOCLONAL ANTIBODIES | |
WO2010021697A3 (en) | Antibodies to ccr2 | |
WO2007058823A3 (en) | Anti-egfr antibodies | |
WO2007109236A8 (en) | Microrna fingerprints during human megakaryocytopoiesis | |
WO2007016548A3 (en) | Micro-rna-based methods and compositions for the diagnosis, prognosis and treatment of breast cancer | |
WO2005103083A3 (en) | Anti-cd38 human antibodies and uses therefor | |
WO2004113277A8 (en) | Methods and compositions for treating amyloid-related diseases | |
WO2003100033A3 (en) | ANTI-αvβ6 ANTIBODIES | |
WO2006071441A3 (en) | Antibodies directed to gpnmb and uses thereof | |
WO2008148546A3 (en) | Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a nir fluorescence label | |
WO2005098433A3 (en) | Diagnostic assays for alzheimer’s disease | |
WO2004067570A3 (en) | Prostate cancer diagnosis and treatment | |
WO2006058720A3 (en) | Novel compounds for the treatment of neurological disorders | |
WO2002061144A3 (en) | Brain tumor diagnosis and outcome prediction | |
WO2003026490A3 (en) | Methods and compositions for prevention, diagnosis, and treatment of cancer using bispecific molecules | |
WO2004015060A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2006108051A3 (en) | Compositions and methods relating to alzheimer's disease | |
WO2004110365A3 (en) | Liver related disease compositions and methods | |
WO2002079398A3 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use | |
WO2002099116A8 (en) | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |